On January 4, 2022, DNA Script SAS closed the transaction. The company amended the terms of the transaction and raised additional funding in the transaction. The transaction included participation from new investors, accounts and funds advised by T. Rowe Price Associates, Inc., Baillie Gifford & Co., HealthCor Management L.P., eureKARE SA, Irving Investors LLC, and Sino Biopharmaceutical Limited.

The company has raised a total of $200 million (€177.12 million) in the transaction. The company has raised a total of $315 million (€278.964 million) in funding till date.